Drug Profile
Evogliptin - Dong-A ST
Alternative Names: DA-1229; RNV-1001; SUGANON; SugarnonLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Alkem Laboratories; Dong-A ST; Eurofarma; GEROPHARM; Luye Pharma Group; REDNVIA; Tobira Therapeutics
- Class Amides; Antihyperglycaemics; Cardiovascular therapies; Fluorobenzenes; Hepatoprotectants; Piperazines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II/III Aortic valve stenosis
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 24 Feb 2023 Dong-A ST plans a phase I trial in Healthy volunteers in South Korea (PO, Tablet) (NCT05739851)
- 22 Feb 2023 Dong-A ST plans a phase I trial in Healthy volunteers in South Korea (PO, Tablet) in March 2023 (NCT05739916)
- 13 Feb 2023 Dong-A ST plans a phase I trial in Healthy volunteers in South Korea (PO) (NCT05739877)